Ketamine Clinics Are Closing: The Bubble Bursts

Ketamine therapy was recently hailed as a miracle treatment for severe depression and anxiety. Investors poured millions into new clinics and telehealth startups. Today, the excitement has faded, and the industry is experiencing a massive contraction. High costs, strict regulations, and changing economic realities are causing a wave of clinic closures across the country.

The Rapid Rise of Ketamine Therapy

The mental health sector experienced a massive shift in 2019 when the Food and Drug Administration (FDA) approved Spravato. This esketamine nasal spray offered a fast-acting solution for treatment-resistant depression. Shortly after this approval, entrepreneurs realized they could legally offer generic, intravenous (IV) ketamine off-label.

Independent clinics opened rapidly in major cities and suburban strip malls. When the COVID-19 pandemic triggered a surge in mental health struggles, the demand for alternative treatments skyrocketed. The federal government also relaxed the rules for prescribing controlled substances via telemedicine during the public health emergency.

This regulatory shift created two distinct business models. First, high-end brick-and-mortar clinics offered supervised IV infusions in spa-like settings. Second, telehealth startups like Mindbloom and Joyous launched aggressive social media campaigns, mailing oral ketamine lozenges directly to patients for at-home use. Venture capital firms invested hundreds of millions of dollars into these companies, betting that psychedelic medicine was the next massive healthcare market.

High-Profile Clinic Closures

The rapid expansion proved unsustainable. The reality of running a specialized medical facility quickly caught up with optimistic revenue projections.

In March 2023, Ketamine Wellness Centers (KWC) abruptly shut down all 13 of its locations across the United States. Patients in states from Arizona to Illinois arrived for their scheduled appointments only to find locked doors. Staff members were terminated without warning. At the time of its closure, KWC was one of the largest ketamine providers in the country.

Field Trip Health, a highly publicized player in the psychedelic therapy space, experienced a similar fate. The company closed five of its North American clinics and restructured its entire business model around the same time. Other smaller, independent providers have quietly closed their doors over the last year, unable to keep up with high overhead costs and dwindling patient numbers.

Financial Realities: High Costs and Low Insurance Coverage

The financial structure of ketamine clinics is the primary reason the bubble burst. Providing supervised IV ketamine is expensive. Clinics must pay for medical doctors, registered nurses, specialized monitoring equipment, and commercial real estate.

Because generic IV ketamine is not FDA-approved for depression, major health insurance companies almost never cover the cost. Patients must pay out of pocket. A single IV infusion typically costs between $400 and $1,000. Medical protocols generally require an initial series of six infusions over two to three weeks, followed by monthly booster sessions. This means a patient might spend $3,000 to $6,000 in their first month of treatment.

When inflation surged and household budgets tightened in 2022 and 2023, fewer Americans could afford these luxury medical expenses. At the same time, venture capital funding completely dried up. Investors stopped writing checks to unprofitable health startups, leaving many clinics without the cash reserves needed to survive a drop in patient bookings.

The Telehealth Crackdown and Regulatory Pressures

While physical clinics struggled with overhead, the telehealth sector faced a completely different threat. Companies mailing ketamine lozenges to patients relied entirely on the temporary suspension of the Ryan Haight Act. This federal law requires an in-person medical evaluation before a doctor can prescribe a controlled substance.

As the COVID-19 public health emergency officially ended, the Drug Enforcement Administration (DEA) signaled its intent to reinstate in-person prescribing requirements. This looming threat caused a panic among investors backing telehealth platforms. If a company like Mindbloom or Joyous suddenly had to require physical doctor visits for their thousands of remote patients, their business models would collapse.

Furthermore, medical professionals and federal agencies began raising serious safety concerns about unsupervised at-home ketamine use. In October 2023, the FDA issued a formal warning regarding compounded ketamine products. The agency noted that taking the drug at home without medical monitoring increases the risk of adverse psychiatric events, elevated blood pressure, and severe dissociation. The lack of standardized dosing in compounded lozenges also led to unpredictable results for patients.

What the Future Holds for Psychedelic Medicine

The closure of retail ketamine clinics does not mean the medicine itself is ineffective. Clinical studies consistently show that ketamine can provide rapid relief for severe depression, anxiety, and post-traumatic stress disorder. However, the delivery method is fundamentally changing.

The industry is currently correcting itself. Moving forward, access to ketamine will likely transition away from standalone, venture-backed retail clinics. Instead, traditional psychiatric offices and comprehensive mental health facilities are beginning to integrate ketamine into their existing practices. This allows doctors to offer the treatment safely without relying on a volume-based business model.

Patients seeking affordable options are also turning toward Spravato. Because it is FDA-approved, it is widely covered by commercial insurance and Medicare, making the out-of-pocket costs manageable for the average person.

Frequently Asked Questions

Why are so many ketamine clinics shutting down? Clinics are closing due to a combination of high operational costs, a lack of insurance coverage for IV treatments, and a severe drop in venture capital funding. Many patients simply cannot afford the high out-of-pocket costs required for ongoing treatment.

Is ketamine therapy still legal? Yes. Ketamine is legally prescribed by doctors. The FDA approved the esketamine nasal spray Spravato for depression in 2019. Traditional IV ketamine is also legally prescribed “off-label” for mental health conditions, though it requires strict medical oversight.

Does insurance cover ketamine treatments? Insurance typically covers Spravato (esketamine) because it has FDA approval for depression. However, health insurance rarely covers off-label IV ketamine infusions or compounded lozenges prescribed through telehealth services.

What happens to patients when a clinic closes? When a clinic shuts down abruptly, patients must find a new provider to continue their care. They must request their medical records and transition to a different local clinic or a traditional psychiatric practice that offers ketamine or Spravato treatments.

Is at-home ketamine safe? The FDA has issued warnings about at-home use of compounded ketamine. Without a medical professional present, patients face higher risks of dangerous blood pressure spikes, severe dissociation, and potential misuse of the controlled substance. Medical experts strongly recommend supervised, in-person treatment.